OptiNose, Inc.

OPTN

US68404V1008

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:55:27 28/05/2024 BST			5-day change	1st Jan Change
1.175 ^USD	+5.86%		+1.29%	-8.91%

05-14	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14	Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	MT

OptiNose Reiterates Revenue Guidance for the Full Year of 2021

July 28, 2021 at 01:00 pm

OptiNose reiterated revenue guidance for the full year of 2021. The company expects XHANCE net revenues for the full year of 2021 to be at least $80 million.

Latest news about OptiNose, Inc.

Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	05-14	MT
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	05-09	CI
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	04-25	CI
Transcript : OptiNose, Inc. - Special Call	04-25
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	04-25	CI
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	04-25	CI
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	03-18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	03-18	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	03-15	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	03-15	DJ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	03-15	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	03-14	CI
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	03-11	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	03-07	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	03-07	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
North American Morning Briefing : Powell Still in -2-	03-07	DJ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	01-18	CI
OptiNose, Inc.(NasdaqGS:OPTN) dropped from NASDAQ Biotechnology Index	12-15	CI
Optinose Shares Slide Premarket as FDA Extends Xhance Review	12-06	DJ
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	12-06	MT

OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OptiNose, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.11 USD

Average target price

3.75 USD

Spread / Average Target

+237.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OPTINOSE, INC.	-8.91%	161M
ELI LILLY AND COMPANY	+37.79%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.45%	328B
ABBVIE INC.	-0.50%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.10%	164B
PFIZER, INC.	-1.84%	164B

Other Pharmaceuticals

OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

OptiNose Reiterates Revenue Guidance for the Full Year of 2021

Latest news about OptiNose, Inc.

Chart OptiNose, Inc.

Company Profile

Income Statement Evolution

Ratings for OptiNose, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals